Russia's RDIF sovereign wealth fund and China's Shenzhen Yuanxing Gene-tech have agreed to produce over 60 million doses of Russia's Sputnik V vaccine against COVID-19 in China, RDIF said on Monday.
RDIF, which is marketing Sputnik V globally, said that commercial production was due to start in May.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3